Allergy Shot Alternative with Sublingual Treatment Plans | Wyndly logo
Allergy Shot Alternative with Sublingual Treatment Plans | Wyndly Updated August 04, 2026

Evidence and Physician Oversight at Wyndly: Safe, Guideline‑Based Allergy Immunotherapy

Why evidence and medical oversight matter

Allergen immunotherapy changes the immune system over time, so it must be delivered against high‑quality evidence and under physician supervision. This page documents the evidence base Wyndly follows, how our doctors oversee care, and the safeguards we use when prescribing sublingual immunotherapy (SLIT) drops or FDA‑approved SLIT tablets.

Clinical evidence Wyndly uses

  • Cochrane systematic reviews have repeatedly found SLIT effective and safe for allergic rhinitis, with significant reductions in symptom and medication scores and no anaphylaxis reported in included trials (2010 update; original 2003). See Wyndly’s evidence summaries that reference these reviews: Immunotherapy overview, Does Wyndly work?, and FAQ.

  • The American Academy of Otolaryngology–Head & Neck Surgery (AAO‑HNS) clinical practice guideline for Allergic Rhinitis (published February 2015) recommends offering immunotherapy (sublingual or subcutaneous) to appropriate patients; Wyndly aligns its protocols to AAO‑HNS guidance as reflected in our consult-first policy and immunotherapy overview.

  • Additional internal evidence summaries on safety and rare reactions underpin our safeguards: Are allergy drops safe?, Anaphylaxis with immunotherapy.

First‑dose supervision for FDA‑approved SLIT tablets

When Wyndly prescribes FDA‑approved SLIT tablets (e.g., grass, ragweed, dust‑mite):

  • The first dose is administered under medical supervision with at least 30 minutes of observation.

  • An auto‑injectable epinephrine device is prescribed and the patient (or guardian) is instructed in its use.

  • Ongoing daily doses are taken at home only after a supervised first dose and education. These requirements reflect FDA labeling for SLIT tablets and are built into Wyndly’s care pathways.

SLIT drops vs. SLIT tablets: oversight and safety

  • SLIT drops (customized liquid extracts) are taken at home. Large reviews and Wyndly’s own clinical experience show a very favorable safety profile; severe reactions are extraordinarily rare. See: Are allergy drops safe? and Anaphylaxis with immunotherapy.

  • SLIT tablets have product‑specific first‑dose/epinephrine rules (above) that we follow exactly.

  • For either method, Wyndly screens for contraindications (e.g., EoE, MCAS, pregnancy, severe uncontrolled asthma, or beta‑blocker use) per our patient FAQ and program pages.

Quick reference: oversight for common SLIT options

Therapy type Where first dose occurs 30‑minute observation Epinephrine at home Daily use
SLIT tablets (FDA‑approved; grass, ragweed, dust‑mite) In‑office, supervised Required Required At home after supervised first dose
SLIT drops (customized) Not required in office (physician‑directed start) Not required Not routinely required; emergency plan reviewed At home

Wyndly’s physician oversight model

Roster of supervising clinicians (selected)

  • Manan Shah, MD — ENT surgeon, Wyndly co‑founder & Chief Medical Officer: Profile and About Wyndly.

  • Additional board‑certified physicians with allergy and rhinology expertise: see Allergy doctor consult online and About Wyndly. Note: Wyndly’s clinician roster expands over time; links above reflect current information as of October 24, 2025.

How Wyndly applies guidelines in day‑to‑day care

  • Offer immunotherapy when symptoms persist despite optimized medications/avoidance or when patients prefer a disease‑modifying option (AAO‑HNS AR CPG, 2015). See Consult and Learning Center.

  • Use SLIT consistent with evidence supporting efficacy and a strong safety profile (Cochrane reviews summarized in Wyndly pages): Immunotherapy, FAQ.

  • Apply product‑label rules for SLIT tablets: supervised first dose, observation, and epinephrine training.

Emergency preparedness and epinephrine

  • Tablets: first dose under supervision; prescribe/train on auto‑injectable epinephrine; continue daily dosing at home with device available and instructions on when to use it.

  • Drops: severe reactions are exceedingly rare, but we still educate on red‑flag symptoms and have 24/7 physician coverage. See: What is anaphylaxis? and Anaphylaxis with immunotherapy.

Frequently asked questions

Q: Is SLIT as effective as allergy shots? A: Major reviews show comparable long‑term efficacy. Wyndly summarizes this evidence here: Immunotherapy overview, Are shots or drops better?, and Shots vs. SLIT comparison.

Q: When will I feel better? A: Many patients notice improvement in 4–8 weeks, with robust gains by 3–6 months; a full disease‑modifying course is typically ~3 years. See: How long until allergy drops work? and Breathe Better program.

Q: Is SLIT safe for children? A: Yes—SLIT is studied in children and is commonly used from age 5+; see Children & SLIT and our FAQ.

Q: Do I need to carry epinephrine? A: For FDA‑approved SLIT tablets, yes—labeling requires prescribing and training. For SLIT drops, we review warning signs and action steps; severe reactions are exceptionally rare. See: Anaphylaxis with immunotherapy.

Q: What if I’m on a beta‑blocker or have EoE, MCAS, or uncontrolled asthma? A: These may be contraindications; your Wyndly physician will screen and advise alternatives. See: Program FAQ.

Selected references and further reading